Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 207

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 207
---
ITEM 1.             FINANCIAL STATEMENTS

Dynavax Technologies Corporation

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

June 30,2025December 31,2024(unaudited) (Note 1) AssetsCurrent assets:Cash and cash equivalents$99,101 $95,883 Marketable securities available-for-sale514,628 617,951 Accounts receivables, net of allowance for doubtful accounts of $12,313 at June 30, 2025 and December 31, 2024, respectively70,699 45,281 Other receivables2,646 1,625 Inventories75,687 70,054 Prepaid expenses and other current assets22,951 18,147 Total current assets785,712 848,941 Property and equipment, net45,610 39,001 Operating lease right-of-use assets20,314 21,608 Goodwill2,200 1,946 Other assets, net of allowance for doubtful accounts of $10,970 at June 30, 202564,613 74,760 Total assets$918,449 $986,256 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$2,702 $9,061 Accrued research and development5,459 4,310 Accrued liabilities65,952 61,066 Convertible Notes, current portion, net of debt discount of $188 at June 30, 2025 (Note 7)40,020 - Other current liabilities4,097 4,197 Total current liabilities118,230 78,634 Convertible Notes, net of debt discount of $4,248 and $1,646 at June 30, 2025 and December 31, 2024, respectively (Note 7)220,752 223,854 Long-term portion of lease liabilities24,726 26,388 CEPI accrual long-term (Note 6)60,337 60,337 Other long-term liabilities242 244 Total liabilities424,287 389,457 Commitments and contingencies (Note 5)Stockholders’ equity:Preferred stock: $0.001 par value, 5,000 shares authorized at June 30, 2025 and December 31, 2024; zero shares outstanding at June 30,